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                                                       INTRODUCTION
                Among all the regional anesthesia techniques subarachnoid block is the easiest to perform 
because of its clearly defined end point and it is most widely used for                 surgeries below the 
umbilicus and lower extremities.
                 The  advantages  of  subarachnoid  block  are  reduced  blood  loss,  attenuation  of 
neuroendocrine response, increase blood flow to lower limbs,  decreased platelet   aggregation,  well 
maintained airway in a conscious patients reduced mortality and marked decrease in hospital cost.
                 In order to prolong the duration of subarachnoid block vasoconstrictors were added to local  
anesthetics but one of the rare outcomes is ischemia of spinal cord.
                Hence the need to find a drug which do not damage the spinal cord but at the same time 
should effectively prolong the duration of spinal anaesthesia could be an α2 agonist  clonidine which 
inhibit  nerve conduction in Aα and C fibers without causing ischemic damage to spinal  cord.
             
                                        
                                                   AIM OF THE STUDY
             1) To assess whether oral clonidine affects the onset and duration of subarachnoid block by 
0.5% hyperbaric bupivacaine.
2)To assess whether oral clonidine affects the onset and duration of subarachnoid block by 
0.5% hyperbaric bupivacaine in a dose related manner.
              3)  To evaluate the side effects and complications that may arise with the use of oral clonidine
                                                     
                                                 
                                                      
                                            ANATOMY
         
              The vertebral column consists of 7 Cervical 12 Thoracic 5 Lumbar and 4 or 5  
Coccygeal vertebrae.
              The vertebral column has 4 curves of which the thoracic and sacral curves are concave 
anteriorly. The cervical and lumbar are secondary and are convex anteriorly. Thus, when the spine is 
fully flexed, the cervical and lumbar curves are obliterated.
             
             The vertebral canal is bounded anteriorly by the bodies of the vertebrae and  intervertebral 
discs. Posteriorly by the laminae, ligamentum flava and the arch which becomes spinous processes with 
ligaments between them, the interspinous ligaments,  and laterally by the pedicles and laminae of the 
vertebrae.
              
CONTENTS
1. Roots of spinal nerves.
2. Spinal membranes with their enclosed cords and CSF.
3. Epidural vessels, fat and alveolar tissue of the extradural space. 
4. Spinal cord begins at the level of foramen magnum as a continuation of medulla oblongata and 
ends below at the conus medularis. Spinal cord lies within the vertebral canal bound together by 
several  ligaments  which  gives  stability  and  elasticity.  The  important  ligaments  are 
supraspinous, interspinous and ligamentum flavum. The spinal cord is protected by both the 
bony vertebral column and the three connective tissue covering the meninges—the duramater, 
the arachnoid matter and the piamater.
           The subarachnoid space is filled with CSF and contains numerous trabeculae which 
form a delicate sponge like mass. The subarachnoid space has 3 divisions. Cranial (surrounding 
the brain) Spinal (surrounding the spinal cord) and Root (surrounding the dorsal and vertebral 
roots). All these compartments are in free communication with each other. There are 31 pairs of 
symmetrically  arranged  spinal  nerves  8Cervical,  12Thoracic,  5Lumbar,  5Sacral  and 
1Coccygeal.
CSF
            It is an ultrafiltrate of plasma and is produced by the choroid plexus in the lateral 
ventricle. It is a clear, colourless fluid found in the spinal and cranial subarachnoid space  and in 
the ventricles of the brain. 
           At 37 degree centigrade, its specific gravity is 1003 to 1009 and  its pH  is 7.4-7.6. The 
total amount varies from 120-150ml of which 25-35ml is in the spinal subarachnoid space. In 
the horizontal position, the CSF pressure ranges from 60-80 mm of water.
DENSITY AND BARICITY
           Density is the weight of one ml of solution at a specific temperature. Baricity is a term 
related to the local anaesthetic used for spinal anaesthesia..  It is the ratio of the density of the  local 
anaesthetic  at  a  specified  temperature to  the density of  CSF at  the  same temperature.    Local 
anaesthetic  solution  with a baricity of less than .9998 at 37deg. centigrade are  hypobaric in all 
patients.  While local anaesthetic solution at 37 deg. centigrade with baricity 1.008 are hyperbaric, 
those  between .9998 and 1.008 are isobaric .
Isobaric
            These tend to remain in the vicinity of  the injection site, both during and after injection and 
are unaffected by movement of the patient after injection.
                                                                                                                                 Hyperbaric
            Hyperbaric solutions are produced by mixing them with dextrose. Barker first introduced 
this technique in 1907. Increasing the density of local anaesthetic solution for spinal use by addition 
of  dextrose3,4 increase  controllability  as  with  the  weighed  solution.  The  movement  is  more 
responsive to position of patient resulting in more easily manageable levels.
             Fink et al concluded that it is unnecessary to use solutions with a dextrose concentrations 
greater than 5% as this was found to be optimal. 
CARBONATED LA SOLUTIONS
            Bromage has recommended the use of a carbonated local anaesthetic solution to prolong 
the duration of anesthetic action. As a weak base, bupivacaine exists largely as a cation and 
does not  readily penetrate the epineurium of nerves  on alkalinizing the solution.  The agent 
exists predominantly as an unchanged  particle which readily penetrates the neuronal membrane 
to establish a high intraneuronal concentration where it readily ionizes in the axoplasm and 
blocks conduction. 
VASOCONSTRICTOR AGENTS
            In 1940, Pitkin stated that addition of  vasoconstrictor agents would result in  reduction 
of  toxicity  of  local  anaesthetic  agents  and  that  the  duration  of anesthesia would be 
prolonged. 
           Ephedrine, Adrenaline and Phenylephrine have been used to prolong spinal anaesthesia. 
Ephedrine is least effective and rarely used. Adrenaline (1:1000)  upto 100mg (0.1 mg) and 
Phenylephrine  1%  solution  (2.5mg)  have  been  added  to  prolong  subarachnoid  blockade 
clinically and experimentally without any adverse effects. Adrenaline and Phenylephrine also 
have  autoreceptive  effects  on  the  dorsal  horn  of  spinal  cord.  Intrathecal  clonidine  is  also 
effective in prolonging the local anaesthesia induced sensory and motor blockade. Racle et al8 
demonstrates that intrathecal clonidine in dose of 0.15mg, prolonged motor (38%) and sensory 
(46%) blockade when used as an adjunct to spinal anaesthesia using bupivacaine. 
         Clonidine is  also effective following oral  administration,  reaching a  peak  plasma 
concentration within 80-90 mines of administration. Although prolongation of local anaesthetic 
induces spinal sensory and motor blockade is well  documented after  co-administration with 
intrathecal clonidine, the effect of oral clonidine remains controversial.
BASIC  PHARMACOLOGY AND CLASSIFICATION OF                   
                         ADRENERGIC RECEPTORS 
                  
                       Until recently , the dual receptor theory of Ahlquist  was the only framework for the 
understanding of adrenergic receptors. Ahlquist  differentiated the adrenergic receptors into α 
and β based on the rank order of potency of various natural and synthetic catecholamines.
 
                    Subsequently Lands and colleagues showed that the rank order of potency of a series of 
catecholamines for a variety of β adrenergic receptor  mediated responses could used to identify 
two types of β adrenergic receptors β1 and β2 .   Both these receptors stimulate the membrane 
bound enzyme adenylate cyclase , leading to the intracellular  accumulation of 3, 5 cyclicAMP , 
a ubiquitous  second messenger present in all tissues.
                       The next major breakthrough was the identification of a receptor in the presynaptic site 
of a adrenergic pathway which regulated the  release of neurotransmitter.  This led a subdivision 
of  adrenoceptors  based  on  the  synaptic   location  into  postsynaptic  and  presynaptic  .  A 
classification based strictly on anatomical location has proven to be untenable in the light of 
postsynaptically  and even extrasynaptically   located   α2 adrenergic  receptors  not  linked to 
neurotransmitter release.  The current pharmacological classification of α2  versus α1 is based 
on  the antagonists Yohimbine and Prazosin  is more potent than Prazosin at α2 receptors.  
         
                               The basic structure is similar to other neurotransmitter receptors.  Each of the  
receptor proteins is comprised of a single  polypeptide chain which weaves back and forth 
through the cell membrane. The main structural difference exists in the cytoplasmic side of the 
receptor which predicates the characteristic adrenergic responses. By providing contact points 
for the  host  of guanine nucleotide binding proteins –the G  proteins in turn signal to a discrete 
effector mechanism which may be a transmembrane ion channel (Efflux of K- or suppression of 
Ca++ entry) or  second  messenger  cascade  (cyclic  AMP or Inositolphosphate ) (Figure I).
PHARMACOLOGY OF α2  Agonists.
 
 The α2 agonists can be grouped into 3 main classes:                                                                 
1. Phenylethylamines              eg   α methyl noradrenaline 
2. Imidazolines                        eg   Clonidine 
3. Oxaloazepines                     eg  Azepexole.       
            The α  adrenergic drugs can be arranged in  order of their selectivity  to α2 and α 1 
receptors as given below:-
α2 Dexmedetomidine
Guanafacine
Clonidine  
Oxymetazaoline
Epinephrine
Norepinephrine
α1  Phenylephrine
Dexmedetomidine, currently under development is most selective with α 2 to α1 ratio of 
2000:1 , whereas clonidine exhibits a selectivity of 300:1.
CLONIDINE
CHEMISTRY
                   
                       An imidazole compound
HISTORY
                      Clonidine was synthesized in 1960 and was originally developed for intranasal 
administration as a nasal decongestant.  Since it is highly lipid soluble  it is not surprising that it 
produced systemic effects  (sedation and hypotension) and its use as a decongestant had to be 
abandoned. 
PHARMACODYNAMICS
             Clonidine is rapidly and almost completely absorbed  after oral administration and the 
bioavailability is nearly 100%   Peak plasma concentration is reached again 60-90 minutes and 
maximal hypotensive effects are observed 1-3  hours after an oral dose.  The elimination half-
life of clonidine is between  6 and 24 hours  (mean 12 hours).  Approximately 50% of the drug 
is metabolized in  the liver to   inactive metabolites while the rest is  excreted unchanged by the 
kidney.
                    
  
  PHARMACOLOGIC EFFECTS OF α2 ADRENERGIC AGONISTS
                                                                                            
                                                     Site                                  Effect          
                         
Cardiovascular               Brainstem;  Spinalcord           Decreased BP. HR
                                       Peripheral vasculature             Increased BP. SVR
                                       Heart                                       Slowed conduction
  
Consciousness               Locus coeruleus         Sedation, anaesthesia 
Pain transmission          Peripheral nerve endings         Reduced  sensitivity 
                                      Brainstem                                 Analgesia 
Respiration                    Brainstem                                Reduced respiratory drive
Hormonal                      Hypothalamus, Pituitary          Decreased ACTH, LH
   
                                                                                       FSH, AVP, Increased GH
                                       Pancreatic islets                      Decreased Insulin
                                       Spinalcord ,   periphery           Decreased
                                                           
                                                                                       Catecholamines  
           
EFFECTS OF  ACTION  OF  CLONIDINE
CENTRAL  NERVOUS SYSTEM
          Clonidine by virtue of its action on the small discrete nucleus of noradrenergic cells in the 
brainstem , the locus coeruleus causes sedation and anxiolysis,  clonidine is a potent analgesic 
by  itself   and  acts  synergistically with  concomitant  Opioids.   Anaesthesia  induced by  α2 
agonists is mediated  through G1 protein and is dependant on inhibition of c-AMP protection.
CARDIOVASCULAR SYSTEM
     Action of clonidine  may be classified as peripheral or central.
PERIPHERAL.
                 Clonidine inhibits noradrenaline release from  the  peripheral  prejunctional  nerve 
endings and this may lead  to bradycardia .   Among the different  vascular beds the effects of 
clonidine on  the coronary circulation  is  important.  Clonidine has been documented to release 
EDRF(  Endothelial  Derived  Relaxant  Factor)  in  coronary arteries  and to  enhance  coronary 
blood  flow induced  by endogenous  and  exogenous  adenosines  in  an   INVIVO MODEL . 
Intravenous clonidine causes a transient hypertensive response due to its direct action on the 
post-synaptic  α2 receptors .  However this effect is not seen when clonidine is administered 
orally. 
CENTRAL
                Clonidine mediated  hypotensive and bradycardia effects have been well recognized. 
The  mechanism  for  these  actions  may  involve  inhibition  of  sympathetic  outflow  and  the 
potentiation of parasympathetic nerve activity.  However the precise mechanism involved in 
these actions is not well understood.  While the nucleus tractus  solitarius is an important central 
site for the action of α2 agonists, other nuclei, including the locus coeruleus , the dorsal motor 
nucleus  of  vagus  and  the  nucleus  reticularis   lateralis   may  also  mediate  hypotension, 
bradycardia or both.  It has been documented that the imidazole – preferring receptors play an 
important role in the hypotensive  effects of clonidine. 
ANTI-ARRHYTHMIC  PROPERTIES.
             Clonidine is capable of preventing adrenaline-induced arrhythmias during halothane 
anaesthesia.  
CEREBRAL CIRCULATION.
            Clonidine has been shown to decrease cerebral blood flow.  This action may be 
favourable in protecting the brain from an abrupt increase in intracranial tension.. 
RESPIRATORY SYSTEM.
                    α2 agonists may produce mild respiratory depression by three mechanisms.
           a.)  Sedation or analgesia can produce a small decrease in respiratory rate due to 
anxiolysis or pain relief
.       b.)  By acting at the α2 receptors close to  the respiratory centre  in the brainstem.
           c.)  By interference of the thermoregulatory control mechanism. 
  
          Respiratory depression is not common and there are only anecdotal reports in literature . 
It  may occur if  massive doses of clonidine  is  used.  There is no potentiation  of  opioid 
induced  respiratory depression by clonidine.  
Nebulized clonidine causes bronchial constriction is asthmatics.                                     
ENDOCRINE SYSTEM
             α2 agonists can decrease stress induced ACTH release and hence cortisol synthesis.
              α2 agonists activate growth hormone release and has been used as a diagnostic tool to test for 
the pituitary glands ability to release growth factor in children.
        Clonidine also inhibits the release of Insulin from the pancreatic β cells directly.
         α2 agonists decrease circulating Norepinephrine and Epinephrine by central and peripheral 
mechanisms.  Centrally they diminish sympathetic outflow by actions in the brainstem and spinalcord. 
Peripherally, they stimulate classical presynaptic autoinhibitory  α2  adrenergic receptors to decrease 
norepinephrine  release.  
GASTROINTESTINAL SYSTEM.
       Hyposalivation is one of the advantages of  clonidine as a  premedicant .  Clonidine is also 
supposed to prevent intestinal ion and water secretion in the large  bowel.
RENAL SYSTEM.
        Clonidine induces diuresis by  
         
a. Inhibition of ADH release
b. Antagonism  of  the  renal tubular action of ADH.                                           
c. Increase in the GFR.
d. Release of atrial natriuretic factor 
HAEMATOLOGICAL SYSTEM
       Clonidine induces platelet aggregation.  It also enhances the aggregatory effects of other drugs.
CLINICAL USES.
              The  ADVANTAGES  of  α2  agonists over other agents used for  anaesthesia  and analgesia 
are      
a. lack significant respiratory depression
b. low abuse potential
c. ability to rapidly reverse therapeutic and pharmacological effects with specific α2 
antagonists.
The DISADVANTAGES of α2 agonists over other agents include 
a. Dry mouth
b. Sedation
c. Bradycardia and 
d. Hypotension  
PRE MEDICATION
               As a premedicant  90-120 minutes prior to induction produces good sedation, maintains 
cardiovascular stability intraoperatively without respiratory depression..
               Clonidine decreases intraocular pressure both before and during surgery.             
                           Combination  of  oral and transdermal Clonidine  at therapeutic levels  to      
provide greater haemodynamic stability.
INTRAOPERATIVE USE
 
Intrathecal  clonidine (150mcg) to potentiate local anaesthetic agents to prolong bupivacaine spinal 
anaesthesia  in elderly  patients undergoing hip  surgery.
         Postoperative  administration  of  extradural  clonidine  to produce effective analgesia in a dose 
dependant fashion – 100-900 mcg in patients after knee orthroplasty or abdominal surgery. 
               Extradural clonidine  for the relief of neuropathic pain (100 – 900 mcg) and as a    therapeutic 
adjunct in the management  of refractory   reflex  sympathetic dystrophy.  
Intrathecal  clonidine in combination with morphine for attenuation of cancer pain and terminal 
pain especially in patients who have developed tolerance to intrathecal morphine.
.
OTHER USAGES.
The major advantage over other general anaesthetic or supplements  is providing haemodynamic 
stability .  Increases in blood pressure and heart rate during tracheal intubation and surgical stress are blunted 
or abolished by α2 adrenergic agonists.
Clonidine  induced  sedation  is  counterbalanced   by  reduced  requirement  for  other  general 
anaesthetics and therefore the recovery time is  actually reduced. 
Clonidine may diminish myocardial ischaemia intra and postoperatively after a single dose, 
providing  an important indication in high risk patients
Systemic  clonidine for postoperative  analgesia  5mcg/kg  intramuscularly
     CONSIDERATIONS FOR USE OF α2  ADRENERGIC AGONISTS IN                             
                                                ANAESTHESIA
Advantages Disadvantages Potential 
Advantages
       Major Preservation of 
haemodynamic stability 
(prevent wild swings in HR & 
BP) 
Anxiolysis/Sedation/Analgesi
a without respiratory 
depression
Hypertension 
(parenteral bolus 
administration)
Preservation of 
renal function in 
presence of insult.
Limitation of 
increase in 
ICP/IOP.
Decrease of 
narcotic induced 
muscle rigidity.
Bronchodilatation.
       Minor Limitation of the use of Hypotension 
potentially toxic 
anesthetic/adjunctive agents. 
Induced hypotension.
Bradycardia
‘rebound’ (only 
after prolonged 
use.)
REVERSAL 
       Clinical effects of clonidine can be reversed by atipamezole. .
PHARMACOLOGY OF BUPIVACAINE
HISTORY
It is an amide linked local anesthetic synthesized by B.A.F Ekenstam in 1957 and introduced 
into clinical practice by Talivuo in 1963.
STRUCTURE
An amino amide local anesthetic having aromatic moiety (benzene ring), which offers 
liphophilicity at one end of the molecule. It is linked by an amide to a tertiary amine, which is 
hydrophilic on the other end of the molecule.
MOLECULAR FORMULA
It displays stereoisomerism: marketed as a racemic mixture containing optically active 
enantiomers, R and S. S-enantiomer has been noted to have a slightly longer duration of action and 
lower systemic toxicity when compared to its R-type.
MECHANISM OF ACTION
The base form is in equilibrium with cationic form outside the axoplasmic membrane. Base 
form diffuses inside the cell and recalibrates with cationic form. It then reaches the local anesthetic 
receptor in the Na+ channel by reversing channel pore while it is in an open state. It prevents Na+ ions 
moving intracellularly.
In addition to this simple sodium channel blockade, it also affects second messenger system 
such as adenylate cyclase and guanylate cyclase and also inhibits synaptic transmission by modification 
of post synaptic receptor (or) presynaptic calcium channel blockade in epidural / subarachanoid 
blockade.
PHYSIOCHEMICAL PROPERTIES
Property Value
Molecular weight 288
Potency ratio 15
Toxicity ratio 10
pKa(25.C) 8.16
Protein binding in %
Maternal 95
Fetal 66
% non ionized at
pH 7.4 17
pH 7.2 11
Partition co-efficient
(25.C, pH 7.4) 346
Anesthetic index 3.0-4.0
ABSORPTION
A biphasic absorption pattern has been found for epidural Bupivacaine. The rapid initial 
absorption following epidural administration is most likely related to high concentration gradient 
between the drug in the solution and in the blood. In addition profound increases in epidural blood flow 
observed during epidural administration of Bupivacaine may contribute to its fast initial absorption 
rate.
Later on, after the local anaesthetic has been taken up into local tissues such as epidural fat, 
absorption will become dependent on tissue blood partitioning, resulting in marked slowing of 
absorption. Estimated total fraction of the dose ultimately absorbed into general circulation is 0.94 with 
mean absorption time 8.6 hours.
Absorption of local anesthetic is directly related to the amount of drug injected, vascularity, site 
injected and tissue binding of local anesthetic at injection site. Bupivacaine will produce lower Cmax 
than less potent and less lipid soluble agents.
DISTRIBUTION
Distribution of local anesthetic has special emphasis in the pregnant patient, because one of the 
organs that will be exposed to the absorbed drug is fetoplacental unit.
PHARMACOKINETICS OF BUPIVACAINE
Elimination half-life t1/2β - 162 minutes
Volume of distribution VDSS - 73 lit
Clearance (lit/min) - 0.6
Hepatic extraction - 0.4
BIODEGRADATION AND ELIMINATION
Liver is the site of metabolism. Two major factors controlling the clearance of the amide-linked 
local anesthetic are hepatic blood flow and hepatic function. The principal pathways are N-
dealkylation, aromatic hydroxylation and amide hydrolysis.
CLINICAL CHARACTERISTICS OF BUPIVACAINE
Property Value
Penetrance Moderate
Duration 6-8 hrs
Infiltration 0.05%
Field block 0.1%
Pudendal / paracervical 0.125%
Epidural analgesia 0.125 – 0.25%
Extradural motor 0.5 – 0.75%
Maximal dose 2mg/kg body weight
ADVERSE EFFECT AND COMPLICATIONS
Central Nervous System Toxicity
Potentially toxic blood level can occur when a drug is injected intravenously, intra arterially or 
a large dose of drug is given into highly vascular area. Risk of CNS toxicity is more because 
Bupivacaine is a highly protein bound drug. Pregnancy is associated with 30% reduction in protein 
binding. This allows for higher brain level of Bupivacaine for a given dose of drug.
Symptoms
Slow speech, jerky movements, tremors, hallucination, and seizure.
Cardiovascular Toxicity36,37
1. Dose dependant depression of contractility
2. Dose dependent depression of conduction and velocity in all conducting tissues. Progressive 
prolongation of ventricular conduction.
3. Predisposition to reentry phenomenon followed by sudden onset of ventricular fibrillation.
4. More affinity for cardiolipin
Toxic plasma concentration is 4-5µg/ml.
                             
                                REVIEW OF LITERATURE
                             
                           Administration of first spinal anaesthesia was by Corning  in the year 1885. He  
attempted to anaesthetise the lower half  of the body of a  patient  by injecting Cocaine into 
subarachnoid space.
ORAL CLONIDINE PRETREATMENT AND SPINAL ANAESTHESIA
                 Pouttu at al studied the effect of oral clonidine premedication on concentrations of 
cortisol  and  monoamine  neurotransmitters  and  their  metabolites  in  cerebrospinal  fluid  and 
plasma10. Forty two healthy male patients aged 19 to 40 years undergoing orthopaedic surgery 
under spinal anaesthesia were studied.
                They were divided into 4 groups: clonidine 4.5microgram/kg orally either 2 hours  
before surgery (group I)  or 4 hours before surgery (group II),  diazepam 0.15 mg/kg orally 
(group  III)  or  placebo  tablet  (group  IV).  Plasma  concentration  of  cortisol,  noradrenaline, 
adrenaline, 3,4 dihydroxyphenyl glycol (DHPG) dihydroxyphenyl acetic acid (DOPAC) were 
assayed  from venous  samples  just  before  premedication  and  just  before  spinal  block.  The 
plasma noradrenaline concentrations of patients in groups receiving clonidine clearly decreased 
as compared with other groups. In group I, the sensory blockade lasted significantly  longer 
than in group III and mean duration of motor blockade was longer in group I than in groups III 
and IV.
         Bonnet et al studied the effects of oral and subarachnoid clonidine on spinal anaesthesia 
with bupivacaine1. Their study was designed to determine the analgesic properties of clonidine and its 
effects on the minimum alveolar concentration of inhaled anaesthetics and the quality and duration of 
spinal anaesthesia with bupivacaine. The comparative effects of oral and subarachnoid clonidine on 
spinal anaesthesia with bupivacaine were studied in 36 patients  scheduled for orthopaedic surgery. 
Patients were allocated randomly into four groups to receive either oral diazepam (10mg in groups I 
and II ) or oral clonidine  (150 microgram and 300 micrograms in group III and IV respectively) as 
premedication. Spinal anaesthesia was performed with 15mg hyperbaric bupivacaine 0.5% plus either 
1ml isotonic saline in groups I,III and IV, or 150 microgram clonidine in group II. They concluded that 
subarachnoid but not oral clonidine significantly prolonged the duration of sensory blockade (time for 
regression to L1 was 157+ /- 21 minutes in group I, 267+/-75 minutes in group II,  168 +/-59 minutes 
in group III and 157+/-22 minutes in group IV) and  the  duration of  motor blockade  (duration of 
grade III  motor block – Bromage scale was 103 +/- 20 minutes in group I,  175+/-68 in group II, 
145+/-43 in group III and 120+/- 19 in group IV). 
         Ota et al studied the effects of oral clonidine on the duration of isobaric
 tetracaine spinal anaesthesia 11. They studied 30 patients who were divided into 3 groups. 
Group I (n = 10) received 0.25 mg of oral triazolam
Group II (n = 10) received 0.15 mg of oral clonidine
Group III (n = 10) received 0.25 mg of oral triazolam and -.75 mg of intrathecal
 phenylephrine.
          All the groups received 15 mg of tetracaine intrathecally in isobaric saline solution. While 
the regression time in groups II and III were significantly longer than those in group I, the regression 
times  were  not  different  between  groups  II  and  III.  The  authors  concluded that  sensory blockade 
produced by the intrathecal administration of tetracaine could be prolonged by premedication with 0.15 
mg  of  clonidine  given  orally.  The  prolongation  is  similar  to  that  produced  by  intrathecal 
phenylephrine.
           Singh et al studied the effect of oral clonidine and intrathecal fentanyl on the onset and 
duration  of  spinal  anaesthesia  produced  by  hyperbaric  tetracaine12.   They  studied  40  adult  males 
undergoing elective surgery. All patients received a crystalloid preload of 300 to 400 ml with lactated 
Ringer solution followed by 5 to 10 ml/kg/hr intraoperatively. The patients were divided randomly into 
4 treatment regimens: Group I: Placebo per os (PO) + tetracaine 12 mg intrathecally (IT); group II: 
Placebo  (PO)  +  tetracaine  12  mg  (IT)  +  fentanyl  10  micrograms  IT:  group  III:  Clonidine  200 
micrograms (PO) + tetracaine 12 mg IT; group IV: Clonidine 200 microgram (PO) + tetracaine 12 mg 
IT + fentanyl 10 microgram IT
             They found that the intrathecal administration of 10 micrograms fentanyl did not 
change  the  onset  or  duration  of  tetracaine-induced  spinal  anaesthesia.  Furthermore,  there  was  no 
significant interaction between clonidine and fentanyl in group IV. They concluded that oral clonidine 
(200 micrograms) shortened the onset time of sensory blockade produced by tetracaine and prolonged 
the duration of sensory and motor blockade. However, clonidine premedication increased the risk of 
hypotension and bradycardia.
            Ota et al conducted a study to evaluate the optimal time for administration of  oral 
clonidine  as  premedication  for  prolonging  the  duration  of  tetracaine  induced spinal  anaesthesia  in 
humans13. Forty male patients scheduled for urologic  surgery were studied. Patients were allocated 
randomly into 4 groups who were  given 15 mg of 0.5% isobaric tetracaine. Patients in group I were 
given 250  micrograms triazolam orally 1 hour before anaesthesia while those in groups II,  III and IV 
were administered 150 micrograms oral clonidine just before anaesthesia, 1 hour and 3 hours before 
anaesthesia respectively. Sensory block was assessed by pin prick. Patients in group II and III had a 
significantly longer duration of sensory blockade (74% to 94%) when compared to patients in group I. 
However this prolonging effect of oral clonidine was not apparent in patients in  group IV. 
They concluded that when administered orally 1 hour before anaesthesia clonidine in a dose of 
150 micrograms produced a significant prolongation of   Spinal anaesthesia produced by tetracaine 
without producing adverse effects.
                    The same group did a study on the dose related prolongation of tetracaine spinal 
anaesthesia by oral clonidine in humans14 Forty seven healthy patients were divided randomly into 4 
groups. All patients received 15 mg tetracaine  intrathecally  in isobaric saline. Patients in group I 
received 0.25 mg triazolam  orally while those in groups II , III & IV received 75 mg , 150 mg and 300 
mg of oral  clonidine respectively. These drugs were administered one hour before anaesthesia  sensory 
block was evaluated by pin prick. Regression time was prolonged significantly  in  all the groups as 
compared to the control   group. The prolongation produced by oral clonidine increased in a dose 
dependent manner and reached a maximal effect at 150 micro grams. 4 patients in group IV developed 
bradycardia ( heart rate < 45 BPM), suggesting that the does of 300 micro grams of oral clonidine  may 
promote bradycardia during spinal anesthesia . 
                   Liu et al studied the effect the oral clonidine on the duration of spinal  anaesthesia produced 
by lignocaine in human volunteers15 . Eight volunteers received 50 mg of lignocaine ( 1.5 % dextrose 
free) both with and with out 0.2 mg oral clonidine 1.5 hour before spinal anaesthesia.  Sensory block 
was assessed by pin prick,   transcutaneous electric  stimulation equivalent  to  surgical  incision  and 
duration of tolerance to   pneumatic  thigh tourniquet.  Motor block at  quadriceps  and gastronemius 
muscles was assessed by isometric force dynamometry. They concluded that pre medication with oral 
clonidine prolonged sensory and motor blockade from lignocaine induced spinal  anesthesia .
                  Omote et  al  evaluated the effects  of oral  triazolam ,  tizanidine and clonidine as 
premedication for tetracaine spinal anesthesia16.Sixty two patients were randomly allocated to one of 
the six groups . Patients in group I ( n = 7) group II (n = 8) and  group III (n = 7) received 13 mg of 
tetracaine intrathecally in 10% glucose solution 2.6 ml. Patients in group IV (n = 13), group V (n = 14) 
and group VI (n = 13 ) received 13 mg of tetracaine intrathecally in a volume of 2.8 ml in 10% glucose 
solution which contained 0.6 mg of phenylephrine. Patients in groups I and IV received 0.25 mg of oral 
triazolam while those in groups II and V received 3 mg of oral tizanidine. Patients in groups III and VI 
received 0.15 mg of oral clonidine.
                    Patients in groups II and  V  or group III and VI needed a significantly longer time for 
regression of  sensory blockade as  compared to  patients  in  groups  I  and IV.  Heart  rate  and blood 
pressure of patients in group VI (clonidine – tetracaine – phenylephrine group) showed significant 
decreases  (P  <  0.05)  after  spinal  anaesthesia.  Hence  they concluded  that  oral  premedication  with 
clonidine  and  tizanidine  prolonged  tetracaine-induced  spinal  anaesthesia.  From  the  viewpoint  of 
prolongation of spinal anaesthesia and the haemodynamic stability, oral premedication with tizanidine 
seems to be useful.
 
                   Goyagi et al studied the effect of oral clonidine premedication on the quality of 
postoperative analgesia by intrathecal morphine17. Twenty six patients were randomly allocated into 2 
groups. Coniine group (n = 13) received oral clonidine 5 micrograms / kg and the control group ( n = 
13) received no clonidine. All patients received hyperbaric tetracaine 12 mg dissolved in 10% dextrose 
and morphine 0.2 mg of spinal anaesthesia. The duration of analgesia ( time to the first request for 
supplemental analgesics ) and motor block were noted. The duration of analgesia in the clonidine group 
was longer than the control group. They concluded that preanaesthetic medication with oral clonidine 
enhances  the  postoperative  analgesia  produced  by  intrathecal  morphine  plus  tetracaine  without 
increasing the intensity of side effects from morphine. 
                    Filos et al studied the effects of orally administered clonidine as premedication in the 
elderly18. To pursue this approach, sedation, intraocular pressure (IOP), and haemodynamic profile of 
two doses of oral clonidine premedication were compared in 60 elderly patients, aged 65 to 82 years, 
who underwent elective ophthalmic surgery under local anaesthesia. Group I (n = 20) received placebo, 
group II (n = 20) received 150 microgram of clonidine (2 to 2.5microgram/kg) and group III (n~20) 
received  300  microgram  of  clonidine  (4  to  4.5  I1g/kg)  in  a  randomized,  double  blind  fashion  . 
Decreases  in  mean  arterial  blood  pressure  were  more  pronounced  and  occured  earlier  after 
300microgram of clonidine (31.4 +/-12.1%, P<0.001) as compared to  150 microgram of clonidine 
(18.1 + 10.9% P <0.001) Throughout the study, 6 patients (30%) in group III (300 microgram clonidine 
treated group), were treated atleast once for hypotension, while no patient in groups I or II required any 
such treatment (P<0.05). Heart rate decreased significantly 18.5 +/- 8.1% (P<0.001) only after 300 
micro gram of clonidine. Clonidine 150 microgram and 300 microgram decreased IOP 32.1 +/- 14.3% 
(P<0.001) and 47.8  +/- 17.2% (P<0.001) respectively. After 150 micro gram of clonidine, patients 
were significantly more sedated as compared to those given placebo (pc0.01) but significantly less 
sedated than after 300 micro gram of clonidine (P<0.01), where sedation persisted more than 6 hours 
postoperatively. The authors concluded that a dose of 150 micro gram of clonidine given orally 90 to 
120 minutes preoperatively to elderly patients managed with local anaesthesia is as effective as a dose 
of  300  micro  gram  in  decreasing  IOP  perioperatively  without  causing  excessive  haemodynamic 
depression and sedation. 
NEURAXIAL ADMINISTRATION OF CLONIDINE
                      Acalovschi at al studied the effect of added α adrenergic agonists, adrenaline versus 
clonidine on spinal anaesthesia with pethidine19. Forty five patients scheduled for orthopaedic surgery 
were divided into three groups. They received spinal anaesthesia with 1 mg/kg of 5% pethidine alone 
or with 200 microgram of adrenaline or 2 microgram/kg clonidine. The onset, extent and duration of 
sensory block (to pin prick) and duration and degree of motor block (Bromage scale) were assessed as 
were the haemodynamic responses, duration of postoperative analgesia and degree of sedation. The 
addition of adrenaline to the pethidine solution prolonged the sensory block (P<0.01) but did not affect 
its onset or extent. A similar potentiation was demonstrated for clonidine (P<0.001). The duration and 
degree of motor block were increased by addition of both adrenaline and clonidine. A tendency towards 
bradycardia  and  a  decrease  of  mean  arterial  pressure  was  potentiated  by  clonidine  but  not  by 
adrenaline. 
Only  the  addition  of  Clonidine  prolonged  the  postoperative  analgesia  (P<0.001),  but  was 
associated with an increased sedation score. The authors concluded that co-administration of adrenaline 
or clonidine with pethidine enhances the intensity and duration of spinal anaesthesia and that addition 
of clonidine prolongs the duration of postoperative analgesia.
                            Mercier at al studied the effect of addition of mini-dose of clonidine to sufentanil on  
combined spinal  and  epidural  analgesia  for  first  stage  of  labour20.  Group I  received  sufentanil   5 
micrograms + clonidine 30 micrograms intrathecally (n = 10) and group II only intrathecal sufentanil 5 
micrograms (n = 11). Analgesia evaluated with the VAS pain scores was better in group I compared 
with group II (P = 0.02) and decreased somewhat slower. Side effects such as hypotension, pruritis and 
sedation were not statistically different between the groups. Nausea  and motor blockade did not occur. 
The authors concluded that the addition of mini dose of clonidine (30 micro grams) to sufentanil (5 
micrograms)  given intrathecally seems to markedly potentiate the analgesia obtained  during the early 
first stage of labour.
                         
                       Klimscha et al compared the haemodynamic and analgesic effects of spinal versus 
epidural  clonidine alone and after  repetitive dosing.23 Forty patients  scheduled for lower extremity 
orthopaedic surgery under continuous spinal or epidural  anaesthesia with bupivacaine 0.5% (initial 
dose 5 mg and 50 mg respectively) were studied. In either spinal or epidural technique, one half of 
patients  received  clonidine  150 micrograms in  addition  to  bupivacaine.  Repeat  doses  of  the  same 
anaesthetic mixture were allowed in cases of subsequent pain. Mean arterial pressure (MAP) and heart 
rate  were  recorded  for  6  hours  after  each  injection.  Duration  of  clinically  useful  anaesthesia  was 
defined as the time from drug administration to first sensation of pain. Intrathecal but not epidural 
clonidine decreased MAP significantly compared with bupivacaine alone. Mean arterial pressure after 
intrathecal clonidine with bupivacaine was lower than epidural clonidine 5 and 6 hours after injection. 
Onset time required to surgical anaesthesia (sensory blockade of T11) did not differ among the four 
groups. Duration of spinal and epidural anaesthesia was increased more than twofold by clonidine. 
                          Girace et al studied the postoperative analgesia after co-administration of clonidine and 
morphine by the intrathecal route in patients undergoing hip replacement.24 Postoperative analgesia 
after intrathecal co-administration of clonidine hydrochloride (75 micrograms) and morphine sulphate 
(0.5mg)  was  compared  with  analgesia  produced  after  either  intrathecal  morphine  0.5mg  or  0.9% 
sodium chloride in 90 patients undergoing total hip replacement under bupivacaine spinal anaesthesia. 
Patient controlled morphine requirements were significantly reduced (P<0.001) postoperatively by both 
by  clonidine  or  morphine  and  morphine  compared  with  control  (saline).  However,  no  significant 
additional  reduction in  postoperative analgesic  requirements  was  seen  with the clonidine/morphine 
combination compared with morphine alone. Visual analog pain scores, although good in all groups at 
all times, were significantly poorer in the control group at 2 hours (P<0.04) and 4 hours (P<0.001) after 
operation compared with both treatment groups, and significantly poorer than the clonidine/morphine 
group at 6 hours (P<0.002) and 24 hours (P<0.008) following surgery. Mean arterial blood pressure 
was  significantly  lower  in  the  clonidine/morphine  group  than  in  the  other  two  groups  (P<0.001) 
between 2 and 5 hours after operation.
                    Seah et al studied the prolongation of hyperbaric bupivacaine spinal anaesthesia with 
Clonidine.28 Forty ASA class  I  and II  patients  scheduled  for  transurethral  prostatic  resection were 
randomly allocated into two groups of twenty each.  In the saline group, 3 ml of 0.5% hyperbaric 
bupivacaine plus 1 ml normal saline was given. In the clonidine group, 1 ml (0.15 mg) clonidine in 
addition to 3ml 0.5% bupivacaine was given. Assessment of the sensory blockade by pin prick, motor 
blockade by Bromage scale and measurement of blood pressure and heart rate were performed after 
injection.  The highest  level  of  sensory blockade and the  time required for  maximal  spread  of  the 
sensory blockade were not significantly different in the two groups. The mean time for two segment 
regression and mean time for regression to L2 were significantly greater in the clonidine group than in 
the saline group (P<0.001). Motor blockade LL was also prolonged in the clonidine group than in the 
control group. Side effects such as hypotension (10 in clonidine group versus 4 in saline group) and 
bradycardia (4 clonidine versus 2 in saline ) occurred commonly in the clonidine group, but all patients 
could be effectively treated with ephedrine and atropine respectively.
                           Bonnet et al studied the dose related prolongation of hyperbaric tetracaine spinal 
anaesthesia by clonidine in humans.30 Forty four ASA physical status I and II patients scheduled for 
orthopaedic surgery were randomly allocated into three groups. All the three groups received 15 mg of 
0.5% hyperbaric tetracaine. Group I(n = 14) received 1 ml isotonic saline while group II (n = 15) 
received  0.5 ml  saline  with  0.5ml  clonidine  (75 micrograms).  Group III  (n  =  15  )  received  1  ml 
clonidine  (150  micrograms).  Sensory  blockade  was  evaluated  by  pin  prick  and  motor  blockade 
according to Bromage’s scale. The level of sensory blockade was comparable in the three groups, but 
the duration was different. The group receiving 75 micrograms clonidine had a 25% prolongation of 
sensory blockade. Coniine in a dose of 150 micrograms prolonged the duration of sensory blockade at 
L2 by 72% and grade III motor blockade by 96%. Colloid infusion and the decrease in diastolic blood 
pressure were significantly greater in the clonidine (150 microgram) group compared to the control 
group. The authors concluded that clonidine produces a dose related prolongation of spinal anaesthesia. 
                                Racle et al studied the prolongation of isobaric bupivacaine spinal anaesthesia with 
adrenaline and clonidine for hip surgery in elderly.8 Sixty ASA class II  or III patients aged 75 years or 
more who were scheduled for orthopedic hip surgery under spinal anaesthesia were included in the 
study.  The subjects were randomly allocated into one of the three groups. All patients received 15 mg 
bupivacaine in 4 ml in the horizontal position. Group I patients, received bupivacaine plus 1 ml normal 
saline, group II patients received bupivacaine plus 0.15 mg clonidine. The segmental level of sensory 
loss was tested using forceps. The time course required for maximal spread of the sensory blockade did 
not differ in the three groups. No difference was observed between mean highest levels of sensory 
anaesthesia. The mean time to two segment regression from the highest level was significantly longer 
in group III than in Group I and II. Mean time for regression to the L2 segment was also significantly 
longer in groups II and III than in group I. This time tended to increase more with bupivacaine plus 
clonidine solution than with bupivacaine plus adrenaline solution. Significant prolongation of motor 
block was also associated with the addition of clonidine.
                              
                                       MATERIALS AND METHODS
This is a prospective, randomized, double blinded, control study. Prior approval was obtained 
from the ethical committee of GOVERNMENT STANLEY MEDICAL COLLEGE AND 
HOSPITAL. The procedure and complications of regional analgesia was explained to them in detail 
and written consent was obtained from them.
Inclusion criteria: 
1 Patients belonging to ASA I and ASA II
2 Age 20-50 yrs
3 Elective lower limb and lower abdominal surgeries under spinal anaesthesia
Exclusion criteria:
1. DM, bleeding disorder or other systemic disorders.
2. Patients who have already received any Opioid drugs or systemic analgesics within prior 24 
hours.
3. Any contraindication for central neuraxial techniques.
4. Patients with known allergy to local anaesthetic or other drugs.
5. Patient refusal for regional technique.
6. Patients belonging to ASA3 and ASA4
The patients were randomy divided into three groups of thirty each. 
        
Group I – placebo
(n =30)              
Received placebo per oral + 12.5mg of hyperbaric 
Bupivacaine 0.5% (2.5 ml)
Group II - clonidine
(n =30) 
Received clonidine per orals 100microgram + 12.5 mg 
of  hyperbaric  bupivacaine 0.5% (2.5 ml).
Group III – clonidine
(n =30)
Received clonidine per orals  150microgram+12.5 mg of 
hyperbaric bupivacaine 0.5% (2.5ml).
        Clonidine or placebo was administered sixty minutes prior to entering the operating room.
        An informed written consent was obtained from each patient prior to the procedure.  No patient 
received any other premedication.
Procedure
           The patients were explained about the procedure of spinal anaesthesia. An 18 gauge intravenous 
cannula was inserted and patients were preloaded with 500 ml of lactated Ringer’s solution.
          The baseline blood pressure and heart rate were recorded using an automated non-invasive 
monitor (L&T). The patients were placed in the lateral decubitus position for lumbar puncture. Under 
strict aseptic precautions, a lumbar puncture was performed through a midline approach using 23 gauge 
spinal needle at the L 3-4 intervertebral space. Once a free flow of cerebrospinal fluid was obtained, the 
local anaesthetic was injected at the rate of 1 ml/3 seconds. After the injection the patient was returned 
to the supine position and retained in that position for at least 20 minutes before being positioned for 
surgery. The table was kept in a horizontal position throughout the procedure. Dermatomal levels of 
sensory anaesthesia were evaluated by pin prick. The levels of pin prick analgesia were studied every 
minute  for  the  first  twenty  minutes  and  then  at  10  minute  intervals  until  analgesia  to  pin  prick 
recovered to the L1 segment.
         The highest sensory levels were noted and the following parameters were evaluated and noted in 
the proforma (Appendix 1).
 
a) Time from injection to attainment of highest level of sensory blockade
b) Time for two segment regression of sensory blockade
c) Time for four segment regression of sensory blockade
d) Time for regression of sensory blockade to L1 segment
e) Time for onset of complete motor blockade. This was assessed and graded at the 
Same time intervals as sensory blockade using the following criteria previously 
described by Bromage.
           Here the number of joints completely blocked in both lower limbs was scored. Only an 
all-or-none decision need then be made at each joint. Thus a score of 0 is assigned for no block 
and 1 for complete block.
   
              6 points = Complete block in both lower limbs
f) Time for recovery of motor blockade to L2 level (hip flexion)
g) Central effects:  Sedation was studied and graded as described by Ramsay et al35
 1.Patient is anxious and agitated or restless,or both.
             
             2.Patient is cooperative, oriented and tranqualized.
             3.Patient responds to commands only.
             4.Patient exhibits brisk response to light glabellar tap or loud auditory stimulus.
             5.Patient exhibits a sluggish response to light glabellar tap or loud auditory   stimulus.
         Intraoperatively, the blood pressure and heart rate were monitored at 1 minute intervals for the 
first ten minutes and later every 10 minutes for one hour.
        All parameters were statistically analysed using the Students ‘t’ test for unpaired observations 
between the groups. The sedation score was analysed using the Chi square test with Yates correction.
       A P value of > 0.05 was taken to be statistically not significant (NS), a P value of <0.05 as 
statistically significant (S), a P value of <0.01 as statistically highly significant (HS) and a P value of 
<0.001 as statistically very highly significant (VHS).
       All the observations recorded are presented in the master charts. (Appendices 2A, 2B,2C, 3A,3B 
and 3C)
                                 OBSERVATION AND RESULTS
  
Age, Weight and Gender
        The mean age of patients in the placebo group was 38.93+/-12.38 years, while that 
in the clonidine-A group was 39.53 +/- 10.82 years and clonidine-B group was 39.40+/-10.60.  The 
mean weight of the patients in the Placebo group was 58.33 +/- 6.29 kg as compared to that in the 
clonidine-A group which was 55.63 +/- 5.56 and in clonidine-B was 56.30+/-5.90 (Table I).
Table I: age, and weight in the two groups studied
      Group
Age (years)
Mean +/- SD
   Weight (kg)
    Mean +/- SD
  
    Placebo
38.93+/-12.38 58.33+/-6.29
 Clonidine-A
39.53+/-10.82 55.63+/-5.56
 Clonidine-B
39.40+/-10.60 56.30+/-5.90
Anova F-test for age F=0.03 P=0.97
      
Anova F-test for weight F=1.67 P=0.19    
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      There was no statistically significant differences in the two groups with respect to age and weight.
       The distribution of male and female patients in the two groups (with percentage) is given in Table 
II.
Table II: Distribution of number (%) of male and female patients in each group
  
 Groups Total
 Placebo Clonidine A Clonidine B  
sex male 21 22 22 65
 female 9 8 8 25
Total 30 30 30 90
χ2=0.11   P=0.95
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Time from injection to attainment of highest sensory blockade
           The mean time  from injection to  attainment of highest sensory blockade in the 
Placebo group was 15.03 +/- 4.15  minutes while that in the clonidine-A group was 12.57+/- 2.30 
minutes while that in clonidine-B was 9.37+/-2.34 (Table IIIa).
Table IIIa: Time taken for attainment of highest sensory blockade
  
Observed 
parameter  Groups Mean Std. Deviation
ANOVA
F-test
Time from injection 
to attainment of 
highest sensory 
blockade.
Placebo 15.03 4.156
Clonidine A 12.57 2.300
Clonidine B 9.37 2.341
F=25.9
P=0.001
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          Intergroup comparision showed a statistically significant difference in the time from injection to 
attainment of highest sensory blockade between the three groups is highly significant. (Table IIIb).
Table IIIb: Intergroup comparison of time taken to attainment of highest sensory blockade
Bonferroni t-test
Observed 
parameter Groups compared
Mean 
differance Sig.
Time from 
injection to 
attainment of 
highest sensory 
block (min)
 
 
 
 
 
Placebo
 
Clonidine A 2.47(*) .007
Clonidine B 5.67(*) .000
Clonidine A
 
Placebo -2.47(*) .007
Clonidine A 3.20(*) .000
Clonidine B
 
Placebo -5.67(*) .000
Clonidine B    -3.20(*)
       
      .000
*  The mean difference is significant at the .05 level.
 
Time for two segment  regression of sensory blockade
              The mean time for two segment regression of sensory blockade in the placebo group was 
66.43 +/- 8.18 minutes while that in the clonidine-A group was 107.23 +/- 14.19 minutes while that in 
clonidine-B group was 127.47+/-15.22 (Table IVa).
Table IVa: Time for two segment regression of sensory blockade
Observed 
parameter
 Groups N Mean Std. Deviation ANOVAF-test
Time for two 
segment regression 
of sensory block 
(min)
 
 
Placebo 30 66.43 8.182
Clonidine A 30 107.23 14.197
Clonidine B
30 127.47 15.222
F=173.8
P=0.001
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             Intergroup comparision of the two segment regression of sensory blockade showed a 
statistically very highly significant difference between the placebo and clonidine-A and clonidine-B 
groups. (P<0.001) (Table IVb).
Table IVb:  Intergroup comparision of two segment regression of sensory blockade
Bonferroni t-test
Parameter 
observed               Groups compared
Mean 
Difference Sig.
  Time for two 
segment 
regression of 
sensory block 
(min)
 
 
 
 
 
Placebo
 
Clonidine A -40.80(*) .000
Clonidine B
-61.03(*) .000
Clonidine A
 
Placebo 40.80(*) .000
Clonidine B -20.23(*) .000
Clonidine B
 
Placebo 61.03(*) .000
Clonidine A 20.23(*) .000
*  The mean difference is significant at the .05 level.
Time for four segment regression of sensory blockade
              The mean time for four segment regression of sensory blockade in the placebo 
group was 110.87 +/- 14.98 minutes, while that in the clonidine-A group was 142.97+/- 
16.51 minutes, while that in clonidine-B was 181.83+/-18.84 (Table Va).
Table Va: Time for four segment regression of sensory blockade 
  Observed 
parameter
 Groups N Mean Std. Deviation ANOVAF-test
Time for four 
segment regression 
of sensory 
blockage (min)
 
 
Placebo 30 110.87 14.989
Clonidine A 30 142.97 16.508
Clonidine B
30 181.83 18.841
F=133.3
P=0.001
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           Intergroup comparison of the four segment regression of sensory blockade showed a statistically 
very highly significant difference between the placebo and clonidine-A and clonidine-B groups 
(P<0.001) (Table Vb).
Table Vb: Intergroup comparison of four segment regression of sensory blockade
 Bonferroni t-test
Parameter 
observed                 Groups compared
Mean 
Difference Sig.
Time for four 
segment 
regression of 
sensory blockage 
(min)
 
 
 
  
Placebo
 
Clonidine A -32.10(*) .000
Clonidine B -70.97(*) .000
Clonidine A
 
Placebo 32.10(*) .000
Clonidine B -38.87(*) .000
Clonidine B
 
Placebo 70.97(*) .000
Clonidine A
38.87(*) .000
Time for regression of sensory blockade to L1 seg                                                                               
          The mean time for regression of sensory blockade to L1 segment in the placebo group was 
168.27 +/- 21.26 minutes, while that in the clonidine-A group was 211.40+\- 19.38 minutes, while that 
in clonidine-B group was 263.33 +/-27.51 (Table VIa).
Table VIa: Time for regression of sensory blockade to L1 segment
 Groups N Mean Std. Deviation
Time for regression 
of sensory block to 
L1 segment (min)
 
 
 
Placebo 30 168.27 21.260
Clonidine A 30 211.40 19.383
Clonidine B
30 263.33 27.510
F=128.7
P=0.001
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                Intergroup comparison of the regression of sensory blockade to L1 segment showed a 
statistically very highly significant difference between the placebo and clonidine-A and clonidine-B 
groups. (P<0.001) (Table VIb).
Table VIb: Intergroup comparison of regression of sensory blockade to L1 segment
Bonferroni t-test
Dependent 
Variable                  Groups compared
Mean 
Difference Sig.
Time for 
regression of 
sensory block to 
L1 segment (min)
 
 
 
 
 
Placebo
 
Clonidine A -43.13(*) .000
Clonidine B -95.07(*) .000
Clonidine A
 
Placebo 43.13(*) .000
Clonidine B -51.93(*) .000
Clonidine B
 
Placebo 95.07(*) .000
Clonidine A
51.93(*) .000
Time for onset of  complete motor blockade
     The mean time for onset of complete motor blockade in the placebo group was 6.20  +/2.55 minutes 
while that in the clonidine-A group was 5.90 +/- 2.21 minutes, while that in clonidine-B group was 
5.97+/-1.45minutes (Table VIIa).
Table VIIa: Onset of complete motor blockade
  Parameter 
observed  Groups N Mean Std. Deviation
ANOVA
F-test
  Time for onset of 
complete motor 
block (min)
 
 
 
Placebo 30 6.20 2.552
Clonidine A 30 5.90 2.218
Clonidine B
30 5.97 1.450
F=0.17
P=0.85
             
5.7
5.8
5.9
6
6.1
6.2
Complete
motor
blockade
Placebo
Clonidine A
Clonidine B
             Intergroup comparison showed no statistically significant difference in the time 
of  onset  of   complete  motor  blockade     between  the  placebo  and  clonidine-A and clonidine-B 
groups (P>0.1) (Table VIIb).
Table VIIb: Intergroup comparison of the onset of complete motor blockade
Bonferroni t-test
Parameter 
observed                Groups compared
Mean 
Difference Sig.
Time for onset of 
complete motor 
block (min)
 
 
 
 
 
Placebo
 
Clonidine A .30 1.000
Clonidine B .23 1.000
Clonidine A
 
Placebo -.30 1.000
Clonidine B -.07 1.000
Clonidine B
 
Placebo -.23 1.000
Clonidine A .07 1.000
 
Time for recovery of motor block to L2 (hip flexion)
    The mean time for recovery of motor blockade to L2 in the placebo group was113.90
+/- 26.26 minutes, while that in the clonidine-A group was 144.10+/- 23.24 minutes, while that in 
clonidine-B was 150.13+/-39.49 minutes (Table VIIIa).
 
Table VIIIa: Time to recovery of motor blockade to L2 (hip flexion)
Parameter 
observed
 Groups N Mean Std. Deviation ANOVAF-test
Time for recovery of 
motor block to L2 
[hip flexion] (min)
 
 
 
Placebo 30 113.90 26.258
Clonidine A 30 144.10 23.240
Clonidine B
30 150.13 39.485
F=12.16
P=0.001
0
20
40
60
80
100
120
140
160
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      Intergroup comparision showed a statistically significant difference in recovery    of
motor blockade to L2 between the placebo and clonidine-A and placebo and clonidine-B groups (Table 
VIIIb),but there is no statistical difference between clonidine-A and clonidine-B group.
Table VIIIb: Intergroup comparison of the time to recovery of motor blockade to L2 (hip flexion)
 
Bonferroni t-test
Parameter 
observed                 Groups compared
Mean 
Difference Sig.
Time for recovery 
of motor block to 
L2 [hip flexion] 
(min)
 
 
 
 
 
Placebo
 
Clonidine A -30.20(*) .001
Clonidine B -36.23(*) .000
Clonidine A Placebo 30.20(*) .001
Clonidine B -6.03 1.000
Clonidine B
 
Placebo 36.23(*) .000
Clonidine A
6.03 1.000
Sedation
               Most of the patients in the clonidine group were sedated intraoperatively while only one 
patient was sedated in the placebo group. The sedation score achieved in these patients was 3, i.e., these 
patients were drowsy but responsive to verbal stimulus. None of the patients had a sedation score of 
four,  five  or  six.  This  data  was  analysed  using  the  Chi  square  test  with  Yates  correction,  which 
indicated a statistically very highly significant difference between the two groups (P<0.001) (Table 
IX).
Table IX: Number of patients who had intraoperative sedation
 
Parameter 
observed
 
group
Placebo Clonidine A Clonidine B
Total
 
Not Sedated 
 
Sedated
28 6 4 38
2 24 26 52
Total 30 30 30 90
χ2=48.5   P=0.001
05
10
15
20
25
30
Sedated Not sedated
Placebo
Clonidine A
Clonidine B
Maximal change in heart rate (∆ HRmax)
          The baseline heart rate and the lowest heart rate achieved during the study period were tabulated 
as shown in Appendix 3A,3B and 3C. The maximal change in heart rate   ( ∆HRmax) from the baseline 
was then derived and the mean and standard deviation of   ∆HRmax calculated in the placebo and the 
clonidine-A and B groups. The  ∆HRmax in the placebo group was -14.73 +/- 8.35 beats/minute while 
that  in  the clonidine-A group was -19.33 +/-  10.04,  while  that  in  clonidine-B was -20.32+/-11.37 
(Table Xa). 
Table Xa:  Maximal change in heart rate (∆ HRmax) from the baseline (+ indicates 
increase, - indicates decrease)
Parameters 
observed
Groups N Mean(BPM) Std. Deviation Std. Error
HR_Change Placebo 30 -14.73 8.346
 Clonidine A 30 -19.33 10.039
 Clonidine B 30 -20.32 11.370
F=2.02
P=0.14
BPM = beats per minute
-25
-20
-15
-10
-5
0
Maximal
change in
heart rate
Placebo
Clonidine A
Clonidine B
Maximal Change in systolic blood pressure ( ∆ SBPmax)
         The baseline systolic blood pressure and the lowest systolic blood pressure achieved during the 
study period were tabulated as shown in Appendix 3A, 3B and 3C. Maximal change in systolic blood 
pressure ( ∆ SBPmax) from the baseline was then derived and the mean and standard deviation of  ∆ 
SBPmax calculated in the placebo and clonidine-A and B groups. The ∆SBPmax in the placebo group was 
-28.23 +/- 12.97 mmHg while that in the clonidine-A group was -33.97+/-41.34mmHg, while that in 
clonidine-B   group    was  -   34.83+/-44.10mmHg. (Table XIa). 
Table XIa: Maximal change in systolic blood pressure (  ∆ SBPmax) from the baseline (+ 
indicates increase, -indicates decrease)
Parameter 
observed  Groups N Mean(mmHg) Std. Deviation Std. Error
SBP_Change
 
 
Placebo 30 -28.23 12.971
Clonidine A 30 -33.97 41.342
Clonidine B 30 -34.83 44.108
F=0.43
P=0.65
 mmHg = millimeters of mercury
-35
-30
-25
-20
-15
-10
-5
0
Change
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blood
pressure
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Maximal change in diastolic blood pressure  ( ∆ DBPmax)
          The baseline diastolic blood pressure and the lowest diastolic blood pressure achieved during the 
study period were tabulated as shown in Appendix 3A, 3B and 3C. Maximal change in diastolic blood 
pressure  (∆DBPmax)  from the  baseline  was thenderived  and the  mean and standard  deviation  of  ∆ 
DBPmax calculated in the placebo and clonidine-A and B groups. The ∆DBPmax in the placebo group was 
-17.93 +/- 13.77 mm Hg while that in the clonidine-A group was -16.83 +/- 10.26 mmHg, while that in 
clonidine-B was -18.04+/-15.03mmHg (Table XIIa). 
Table XIIa: Maximal change in diastolic blood pressure (∆ DBPmax) from the baseline 
(+ indicates increase, - indicates decrease)
 N Mean(mmHg) Std. Deviation Std. Error
DBP_Change
 
 
Placebo 30 -17.95 13.771
Clonidine A 30 -18.05 10.256
Clonidine B 28 -18.20 15.027
F=0.08
P=0.93
 mmHg = millimeters of mercury
-18.2
-18.15
-18.1
-18.05
-18
-17.95
-17.9
-17.85
-17.8
Change
in
diastolic
blood
pressure
2nd Qtr 3rd Qtr 4th Qtr
Placebo
Clonidine A
Clonidine B
Maximal change in the mean arterial pressure ( ∆ MAPmax)
           The baseline mean arterial pressure and the lowest mean arterial pressure achieved during the 
study period were tabulated as shown in Appendix 3A, 3B and 3C. Maximal change in mean arterial 
pressure (∆MAPmax) from the baseline was then derived and the mean and standard deviation of ∆ 
MAPmax calculated in the placebo and clonidine-A and B groups. The  ∆ MAPmax in the placebo group 
was -24.07 +/- 10.19mmHg while that in the clonidine-A group was -24.13 +/- 11.06 mmHg, while that 
in clonidine-B group was -25.47+/-10.86mmHg (Table XIIIa). 
Table XIIIa: Maximal change in mean arterial pressure ( ∆ MAPmax) from the baseline (+ indicates 
increase, -indicates decrease)
Parameter 
observed
 Groups N Mean(mmHg) Std. Deviation Std. Error
MAP_Change
 
 
Placebo 30 -24.07 10.191
Clonidine A 30 -24.13 11.057
Clonidine B 30 -25.47 10.859
F=0.16
P=0.85
 
mmHg = millimeters of mercury
-25.5
-25
-24.5
-24
-23.5
-23
Change in
mean
arterial
blood
pressure
2nd Qtr 3rd Qtr 4th Qtr
Placebo
Clonidine A
Clonidine B
                                             
        
                                    
                                                      DISCUSSION
          Vasoconstrictors have been used as adjuncts to prolong the duration of local anaesthetic-induced 
subarachnoid blockade. Prolongation of the local anaesthetic blockade has been attributed to localized 
vasoconstriction,  thereby decreasing  the  uptake  of  local  anaesthetics  from the subarachnoid space. 
Collins et al suggested that intrathecal adrenaline directly stimulated α2  adrenergic receptors in the 
spinal  cord  dorsal  horn  and  exerted  an  antinociceptive  effect  through  the  descending  inhibitory 
pathways in the spinal cord33. In these descending inhibitory adrenergic pathways, noradrenaline is the 
neurotransmitter  responsible  for  suppressing  the  activation  of  spinal  cord  dorsal  horn  neurons  by 
noxious stimuli.
         In addition to vasoconstrictors, intrathecal clonidine is also effective in prolonging the local 
anaesthetic-induced sensory and motor blockade .While Ota et al11 reported that oral clonidine (0.15 
mg), prolonged the duration of tetracaine sensory analgesia by 93%, Bonnet et all1 failed to demonstrate 
significant prolongation of the bupivacaine-induced sensory and motor blockade following clonidine 
0.15 mg or 0.3mg orally.  We found that oral  clonidine 0.10mg, 0.15mg prolonged the duration of 
bupivacaine-induced sensory blockade (regression to L1 segment) by 44%, 61% and motor block by 
44%, 46% respectively.  We also observed that oral clonidine 0.10mg, 0.15mg decreased the time taken 
for  attainment  of  the  highest  level  of  sensory  blockade,  it  was  12.57  minutes&  9.37  minutes 
respectively, when compared to the placebo group which was 15.03 minutes. However, oral clonidine 
did not affect the onset of complete motor blockade. These findings are in concurrence with those 
observed  in  earlier  studies10,12,15,17,18.   Racle  et  al  demonstrated  that  intrathecal  clonidine  (0.15mg) 
prolonged motor (38%) and sensory (46%) blockade when used as an adjunct to spinal anaesthesia with 
bupivacaine  in  humans8  However,  the  effect  of  oral  clonidine  on  subarachnoid  local  anaesthetic 
blockade in humans is controversial. .Although there is clinical and experimental evidence that alpha2 
adrenergic agonists produce their central effects by binding to alpha2 adrenergic receptors in the spinal 
cord,  Butterworth  and  Strichartz  have  demonstrated  in  animal  experiments  that  analgesia  after 
neuraxial  administration of alpha  2 adrenergic agonists  may in fact  result  from direct  inhibition of 
impulse conduction in Aα and C fibres.34
          Clonidine has been demonstrated to potentiate inhibitory effects of local anaesthetics on C fibre 
activity. Previous studies suggest that clonidine also may affect peripheral sensory nerves as a sole 
agent or in combination with local anaesthetics. Therefore, oral clonidine may exert its effects within 
the central nervous system, at peripheral nerve roots, or by potentiation of effects of local anaesthetics.
         Haemodynamic consequences such as bradycardia and hypotension were seen more frequently 
when the dose of oral clonidine exceed 150µg.14  In our study, the dose of oral clonidine was restricted 
to 100µg & 150µg. This could have resulted in the lower incidence of bradycardia (one patient) and 
hypotension (one patient). Both these patients responded effectively to intravenous atropine (0.6 mg) or 
ephedrine (6 mg) respectively.
         Crystalloid preloading in a dose of 300 to 400 ml followed by 5 to10 ml/kg/hr intraoperatively 
could not prevent significant bradycardia and hypotension associated with spinal anaesthesia following 
oral clonidine premedication.12  The use of a larger volume for preloading (500 ml of lactated Ringer’s 
solution) prior to the administration of anaesthesia as performed in our study could probably have 
resulted in an extremely low incidence of bradycardia and hypotension (one patient each). 
        In our study, we noticed that patients premedicated with clonidine had a very high incidence of 
mild sedation when compared to the placebo group. This finding is in agreement with the results of 
previous studies where oral clonidine was used as a premedicant. 18
                                               CONCLUSION
                                 Pretreatment with 100 micrograms & 150 micrograms of clonidine 
hydrochloride   administered orally  60  minutes   prior  to spinal anaesthesia with 0.5% hyperbaric 
bupivacaine.
1) Hastens the onset of sensory blockade but does not affect the onset of motor blockade. 
2) Prolongs the duration of both sensory and motor blockade.
3) Produces significantly higher incidence of mild sedation intraoperatively
4) The  duration  of  both  sensory  and  motor  blockade  is  increased  when 
premedicated with 150 microgram of clonidine compare to 100 microgram of clonidine 
with the side effects comparable in both the groups
.
5)  Is not associated with any greater change in heart rate and blood pressure   than that seen 
following spinal anaesthesia without clonidine premedication.
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